- Home
- NEGG vs IKT Comparison
NEGG vs IKT Comparison
Compare NEGG & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- IKT
- Stock Information
- Founded
- NEGG 2001
- IKT 2008
- Country
- NEGG United States
- IKT United States
- Employees
- NEGG N/A
- IKT N/A
- Industry
- NEGG Other Specialty Stores
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- IKT Health Care
- Exchange
- NEGG Nasdaq
- IKT Nasdaq
- Market Cap
- NEGG 122.3M
- IKT 140.5M
- IPO Year
- NEGG 2010
- IKT 2020
- Fundamental
- Price
- NEGG $42.55
- IKT $1.56
- Analyst Decision
- NEGG
- IKT Buy
- Analyst Count
- NEGG 0
- IKT 2
- Target Price
- NEGG N/A
- IKT $8.00
- AVG Volume (30 Days)
- NEGG 2.2M
- IKT 92.8K
- Earning Date
- NEGG 08-29-2025
- IKT 11-13-2025
- Dividend Yield
- NEGG N/A
- IKT N/A
- EPS Growth
- NEGG N/A
- IKT N/A
- EPS
- NEGG N/A
- IKT N/A
- Revenue
- NEGG $1,313,127,000.00
- IKT N/A
- Revenue This Year
- NEGG N/A
- IKT N/A
- Revenue Next Year
- NEGG N/A
- IKT N/A
- P/E Ratio
- NEGG N/A
- IKT N/A
- Revenue Growth
- NEGG N/A
- IKT N/A
- 52 Week Low
- NEGG $3.32
- IKT $1.12
- 52 Week High
- NEGG $137.84
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- NEGG 44.50
- IKT 42.51
- Support Level
- NEGG $33.52
- IKT $1.50
- Resistance Level
- NEGG $48.15
- IKT $1.73
- Average True Range (ATR)
- NEGG 8.30
- IKT 0.09
- MACD
- NEGG -1.95
- IKT -0.02
- Stochastic Oscillator
- NEGG 30.02
- IKT 17.34
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.